Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

Aarti Industries - Q4FY22 Result Update - Healthy Q4; eyes on capacity ramp-up - Accumulate

Posted On: 2022-06-06 18:36:16 (Time Zone: IST)

Nilesh Dhoot - Research Analyst Prabhudas Lilladher Pvt. Ltd.

Quick Pointers:

- Continuing shortage of nitric acid (key RM) in Q4, impacted volumes of nitric acid based products. Plans to setup concentration capacity of 225-250 TPD to mitigate supply shortfall; also evaluating a comprehensive nitric acid strategy.

- Major expansion projects (second & third long-term contract, pharma US FDA expansion, NCB capacity expansion) expected to come on-stream in FY23. Capex guidance for FY23-24 at ~Rs 30-35 bn (FY22 capex at Rs 13 bn).

- Q4FY22 Revenue/ EBITDA/ PAT growth of 45%/30%/42% YoY led by improvement in realizations (cost pass through) and volumes (restricted due to shortage of nitric acid). Commencement of revenue generation from long-term contracts and ramp-up of recently commissioned plants to drive specialty chemical revenue while pharma revenue to be driven by higher volumes from regulated markets, value-added products and new intermediate products. Upcoming projects to aid penetration in some key therapies (anti-hypertension, cardio-vascular, oncology, corticosteroids).

- We expect healthy revenue/ EBITDA/ PAT CAGR of 18%/20%/24% over FY22-24E, on increasing capacity utilization (high capex intensity of Rs 45-50 bn over FY22-24E, with focus on high value derivatives) leveraging import substitution, rising domestic demand and China +1 strategy. We assign 'Accumulate' rating with TP of Rs 880 (19x FY24E EV/EBITDA).

- Q4FY22 performance healthy, amidst challenges: Consolidated net revenue +45% YoY/ +0.6% QoQ to Rs 17.5 bn (adjusted for Rs 6.3 bn termination fees in Q3FY22) led by improvement in realizations (cost inflation pass through) and volume growth. Spec chem gross revenue was up 49% YoY/ -2% QoQ to Rs 16.3 bn while Pharmaceutical gross revenue was up 52% YoY/ 12% QoQ to Rs 3.9 bn. Gross margin - 630bps YoY/ +140bps QoQ at 47.5% on lag in full pass through of higher costs. EBITDA +30% YoY/ -5% QoQ to Rs 3.4 bn; EBITDA margin at 19.3% (-220 bps YoY / -110 bps QoQ) on higher other operating expenses. EBIT margins for pharma at 17.2% (-280bps YoY/ stable QoQ) while that for spec chem was 15.1% (-380bps YoY/ -200bps QoQ).

- Meeting takeaways: (1) Production of NCB was 19,550 mt in Q4FY22 (vs 19,100 YoY and 18,500 mt QoQ), hydrogenated products was 3,029 tpm (1935 tpm YoY and 2878 QoQ), nitro toluene was 5155 tons (vs 2935 YoY and 3630 QoQ) (2) Volume growth of 10-12% in Q4 and ~18-20% in FY22 (3) Dyes and pigments to witness weakness in demand, while agrochemicals expected to continue strong. (4) Long term contracts - Expect ~70-80% capacity utilization by FY24. Commercial manufacturing of second long-term project related contract commenced in Q4. (5) Nitric acid concentration plant (225-250 tpd) expected to commercialize plant by FY24 end (outlay Rs 1.5-2 bn on this plant). (6) NCB expansion - Phase 1 delay on logistics and labour availability issues. Phase 2 commissioning in FY23.

Shares of Aarti Industries Limited was last trading in BSE at Rs. 714.35 as compared to the previous close of Rs. 720.85. The total number of shares traded during the day was 117639 in over 9257 trades.

The stock hit an intraday high of Rs. 725.90 and intraday low of 708.50. The net turnover during the day was Rs. 84329753.00.

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Gladiator Stocks - Minda Industries - ICICI Direct

Reliance Industries - Company Update - In fine fettle amidst global uncertainty - BUY

Sector Update - Sugar - ICICI Direct

Initiating Coverage - Hindustan Aeronautics Ltd - ICICI Direct

Rallis India - Company Update - Margin pressure likely to persist in near term..!! - Upgrade to 'BUY'

Indoco Remedies - Q4FY22 Result Update - In-line quarter; strong revenue guidance for US & EU mkt - Upgrade to 'BUY'

Indraprastha Gas - Q4FY22 Result Update - Impressive performance - BUY

KEC International - Annual Report Analysis - Healthy outlook across business segment - Accumulate

Westlife Development - Q4FY22 Result Update - Approaching the tipping point; Buy for LT Gains

Reliance Research downgrades Bajaj Auto to Sell

NOCIL - Q4FY22 Result Update - Strong operating performance amidst challenges - BUY

Gujarat Gas - Company Update - Deftly negotiating through tough times - BUY

Orient Electric - Gaining market share via innovation: initiate with ADD - ICICI Securities

Manappuram Finance - Q4FY22 Result Update - Intense Competition Put Pressure on Yields - BUY

Derivatives Weekly View - June 24, 2022 - ICICI Direct

Stock Tales - Newgen Software - ICICI Direct

Weekly Report - June 25, 2022 - Mr. Mitul Shah - Head of Research at Reliance securities

Gladiator Stocks - Bosch - ICICI Direct

Management Meet Update - Sheela Foam - ICICI Direct

Gladiator Stocks - Mahindra & Mahindra - ICICI Direct

Banks - Modifications to PPI and its impact on cards - Negligible impact, if any, for stocks under coverage

LIC Housing Finance - Q4FY22 Result Update - Fixed rate liabilities could cushion NIM - BUY

Navneet Education - Q4FY22 Result Update - Growth levers in place - BUY

MPC Minutes: Jun-22: All eyes on inflation - Acuité Ratings

Nazara Technologies - Management Meet Update - Breaking through the ESports landscape - BUY

Sector update - Quick Service Restaurants - YES Securities

JK Lakshmi Cement - Q4FY22 Result Update - Strong performance; Valuations drive upgrade - Accumulate

Would it be wise to invest in a home early in your career?

Dr. Reddy's Laboratories - Analyst Meet Update - Multiple growth initiatives - BUY

Dhanuka Agritech - Management Meet Update - 1Q likely to be subdued; all hopes pinned on the monsoons - BUY

BUY Ipca Laboratories - Q4FY22 Result Update - Weak exports; gradual recovery

Acuité expects India's current account deficit to widen to more than USD 90 bn in FY23 - Acuité Macro Pulse

Inflationary concerns will continue to weigh on the pace of economic revival in FY23 - Acuité Macroeconomic Performance index

City Union Bank - Q4FY22 Result Update - Asset quality on the mend - BUY

Banks - BNPL - Early results are not that exciting as yet - Kotak

Acuité expects FY23 GDP growth estimate at 7.5% - Acuité Macro Pulse - Growth - May-22 Edition

Base factor pushes up IIP in Apr-22 to an 8-month high - Acuité Ratings

India Strategy & Q4FY22 Review - Long term growth prospects to overshadow near term uncertainties

India Equity Strategy - Quarterly flipbook: Q4FY22-Cost inflation driving downgrades

FMCG - D2C is here to stay; omni-channel the way forward - HDFC Securities

Automobile Sector - Monthly Quick View - May'22 - Steady Performance Improvement, backed by Gradual Rural Recovery

BFSI - New normal rate cycle; brace for transmission effects - HDFC Securities

SBI Cards and Payment Services - BUY - TP Rs. 1260 - YES SECURITIES

RBI frontloads rate hike amid increased inflationary headwinds - Acuité Ratings

Monetary Policy June 2022 - Axis MF Views

RBI Monetary Policy View - Mr. Dhiraj Relli, MD & CEO, HDFC Securities

Monetary Policy - entering the red zone - Anuj Puri, ANAROCK

Mr. Murali Ramakrishnan, MD &CEO, South Indian Bank on RBI Monetary Policy

Comments on RBI's MPC Policy Jun'22 - Acuité Ratings

Views on RBI Monetary Policy - June 2022

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020